Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma

• Published in: Japanese journal of clinical oncology 2021-03, Vol.51 (3), p.315-320
• Main Authors: Kiniwa, Yukiko, Okuyama, Ryuhei
• Format: Article
• Language: English
• Subjects: Brain Neoplasms - drug therapy; Humans; Melanoma - drug therapy; Melanoma - genetics; Melanoma - pathology; Molecular Targeted Therapy; Mutation - genetics; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; Proto-Oncogene Proteins B-raf - genetics; Skin Neoplasms - drug therapy; Skin Neoplasms - genetics
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyaa222

Abstract The clinical outcome of BRAF-mutated advanced melanoma has been improved by both molecular targeted therapies and immune checkpoint inhibitors. Long-term follow-up data reveal durable clinical responses in patients receiving first-line combinations of BRAF inhibitors plus MEK inhibitors, particularly those showing a complete response. Clinical outcomes are also associated with the lactate dehydrogenase levels and the number of metastatic organs. Although brain metastasis is frequently difficult to control, systemic therapy is preferred in cases with small and asymptomatic brain metastases associated with progressive extra-cranial disease. Control of intra-cranial disease with BRAF inhibitors plus MEK inhibitors is comparable with that of immune checkpoint inhibitors, although immune checkpoint inhibitors are superior to targeted therapies with respect to survival. The BRAF inhibitors plus MEK inhibitors regimen is well-tolerated, and toxicities are usually manageable and reversible, but differ according to the specific regimen used. Guidelines in the United States, Europe, and Japan recommend targeted therapy for patients who need early tumor responses. A meta-analysis of retrospective data shows that the baseline lactate dehydrogenase level is significantly higher in patients treated with BRAF inhibitors plus MEK inhibitors than in those treated with immune checkpoint inhibitors, suggesting that clinicians tend to use BRAF inhibitors plus MEK inhibitors for more advanced disease. Since there is insufficient efficacy and safety data on the use of targeted therapies for acral and mucosal melanoma, a retrospective analysis may be useful. The combination of molecular targeted therapy plus immune checkpoint inhibitors is expected to elicit further improvement. The results of several trials using combination or sequential therapies will be available in the next few years. Long-term follow-up data of clinical trials reveals durable responses in patients receiving combinations of BRAF inhibitors plus MEK inhibitors for BRAF-mutated melanoma, particularly in those showing a complete response.